home / stock / prfx / prfx articles

PRFX Articles, PainReform Ltd.

Stock Information
Company Name: PainReform Ltd.
Stock Symbol: PRFX
Market: NASDAQ
Website: painreform.com
Menu
PRFX PRFX Quote PRFX Short PRFX News PRFX Articles PRFX Message Board
Get PRFX Alerts

News, Short Squeeze, Breakout and More Instantly...
Why Adobe Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket | Benzinga

Shares of Adobe Inc. (NASDAQ:ADBE) rose sharply in today's pre-market trading following better-than-expected second-quarter earnings and stron...
Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session | Benzinga

Shares of Signet Jewelers Limited (NYSE:SIG) fell sharply during Thursday's session following mixed first-quarter earnings including an 8.9% d...

Why Broadcom Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket | Benzinga

Shares of Broadcom Inc. (NASDAQ:AVGO) rose sharply in today's pre-market trading after the company posted stronger-than-expected results for i...

Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session | Benzinga

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial res...
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session | Benzinga

Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6...

Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket | Benzinga

Shares of PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for...

EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions | Benzinga

PainReform Ltd (NASDAQ:PRFX) announced results from new studies demonstrating the superior in-vitro release (IVR) rates of PRF-110 compared to...
EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug | Benzinga

On Tuesday, PainReform Ltd (NASDAQ:PRFX) announced it reached the 50% enrollment target for the second part of the Phase 3 clinical trial...

PainReform to Present at the Microcap Conference in Atlantic City | Benzinga

TEL AVIV, Israel, Jan. 22, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-st...

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds | Benzinga

TEL AVIV, Israel, Dec. 26, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-st...
Next 10